Cardiovascular event rate and death in high-risk secondary prevention patient cohort in Finland: A registry study.
atherosclerosis
cardiovascular diseases
cardiovascular risk factors
myocardial infarction
real-world evidence
retrospective study
secondary prevention
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
01
03
2022
received:
08
12
2021
accepted:
03
03
2022
pubmed:
16
3
2022
medline:
22
4
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
A large number of patients are living with atherosclerotic cardiovascular (CV) disease and thus are at risk of life-threatening CV events. This study evaluated the risk for a recurrent CV event or death in Finnish real-world data. Patients with an incident atherosclerotic CV event between 2012 and 2016 were included in this retrospective registry study and followed for recurrent CV events or death. The risk and risk factors of recurrent CV events or death and time from the first CV event to recurrence were assessed. A total of 48,405 patients were followed from their first CV event. The event rate was 14.34 events per 100 patient-years. Multistate models suggested that at 5 years post index CV event, 41.5% of the patients had died or suffered a recurrent CV event. Death was the most common type of subsequent event (61.5%). After the first CV event, there were rapid increases both in recurrent CV events and deaths during the next 6 months. The subsequent CV event was usually of the same type as the first, which was of the cardiac or cerebrovascular cluster. The incidence of recurrent CV events and all-cause mortality was high in patients suffering from their first CV event, particularly during the first 6 months after the index event. Death was the most common subsequent event. The event rate accelerated after each additional CV event. This suggests that the acute treatment of the index event should be followed by prompt secondary prevention measures to achieve guideline-recommended goals as soon as possible.
Sections du résumé
BACKGROUND
BACKGROUND
A large number of patients are living with atherosclerotic cardiovascular (CV) disease and thus are at risk of life-threatening CV events.
HYPOTHESIS
OBJECTIVE
This study evaluated the risk for a recurrent CV event or death in Finnish real-world data.
METHODS
METHODS
Patients with an incident atherosclerotic CV event between 2012 and 2016 were included in this retrospective registry study and followed for recurrent CV events or death. The risk and risk factors of recurrent CV events or death and time from the first CV event to recurrence were assessed.
RESULTS
RESULTS
A total of 48,405 patients were followed from their first CV event. The event rate was 14.34 events per 100 patient-years. Multistate models suggested that at 5 years post index CV event, 41.5% of the patients had died or suffered a recurrent CV event. Death was the most common type of subsequent event (61.5%). After the first CV event, there were rapid increases both in recurrent CV events and deaths during the next 6 months. The subsequent CV event was usually of the same type as the first, which was of the cardiac or cerebrovascular cluster.
CONCLUSIONS
CONCLUSIONS
The incidence of recurrent CV events and all-cause mortality was high in patients suffering from their first CV event, particularly during the first 6 months after the index event. Death was the most common subsequent event. The event rate accelerated after each additional CV event. This suggests that the acute treatment of the index event should be followed by prompt secondary prevention measures to achieve guideline-recommended goals as soon as possible.
Identifiants
pubmed: 35289408
doi: 10.1002/clc.23814
pmc: PMC9019873
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-351Subventions
Organisme : Amgen Finland
Organisme : Amgen Inc.
Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
Références
Adv Ther. 2022 Jan;39(1):314-327
pubmed: 34718949
Adv Ther. 2021 Sep;38(9):4695-4708
pubmed: 34312813
JAMA Cardiol. 2018 Sep 1;3(9):823-828
pubmed: 30073316
Eur J Prev Cardiol. 2019 May;26(8):824-835
pubmed: 30739508
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Prev Med Rep. 2017 Mar 18;6:203-209
pubmed: 28373930
Eur J Prev Cardiol. 2021 Jul 23;28(8):884-892
pubmed: 32013604
Stroke. 2000 Sep;31(9):2080-6
pubmed: 10978033
Int J Cardiol. 2015 Dec;201 Suppl 1:S1-7
pubmed: 26747389
Clin Cardiol. 2022 Apr;45(4):342-351
pubmed: 35289408
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Lancet Neurol. 2014 Feb;13(2):178-94
pubmed: 24361114
J Med Econ. 2017 Jun;20(6):555-564
pubmed: 28097904
J Am Coll Cardiol. 2018 Nov 6;72(19):2297-2305
pubmed: 30384885
Am Heart J. 2017 May;187:194-203
pubmed: 28454804
Clin Cardiol. 2015 Aug;38(8):483-91
pubmed: 26100722
Eur Heart J. 2015 May 14;36(19):1163-70
pubmed: 25586123
Stroke. 2019 Mar;50(3):675-682
pubmed: 30776996
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):225-232
pubmed: 30649251
J Am Heart Assoc. 2018 Jan 18;7(2):
pubmed: 29348322
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804